HOLON, Israel, March 5, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and developmentof first-in-class therapeutics for cancer immunotherapy, today announced that John Hunter, PhD, Chief Scientific Officer, will present a corporate overview and update at the Cowen and Company 39th Annual Health
A live webcast of the presentation will be available on Compugen's website. A replay will be available after the presentation ends.
Compugen is a therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with facilities in both Israel and South San Francisco, CA. Compugen's shares are listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.
Company contact:Elana HolzmanDirector, Investor Relations and Corporate CommunicationsCompugen Ltd.Email: firstname.lastname@example.orgTel: +972(3)765-8124
Investor Relations contact:Burns McClellan, Inc.Jill SteierEmail: email@example.com Tel: 212-213-0006
View original content:http://www.prnewswire.com/news-releases/compugen-to-present-at-the-cowen-and-company-39th-annual-health-care-conference-300806583.html
SOURCE Compugen Ltd.
Subscribe to our Free Newsletters!